The global anti-obesity therapeutics market is forecasted to grow at a CAGR of above 20.0%. On account of increasing prevalence of obesity worldwide. Incidences of obesity are increasing fiercely over the past decades and it is often described as a global endemic, particularly in the developed countries.
It is primarily due to the faulty eating habits and rapidly changing the lifestyle of individuals. Rising consumption of fast foods coupled with the lack of exercise is expected to intensify the rising number of obese patients worldwide. Increasing disposable income is promoting the consumption of unhealthy fast foods, which will drive the market demand for anti-obesity therapeutics.
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
Fundamental treatments exist like regulating the intake of unhealthy food and inculcating exercise as a part of daily routine because the effectiveness of these anti-obesity drugs is limited to retain the same weight rather than an antidote. Obesity is on the rise mainly due to less sleep, lack of physical activity, high-calorie diet, additionally heredity and family history plays a pivotal role. Consumption of certain medicines also results in obesity.
Rising concern of being overweight or obese is exposing individuals to the major risk of development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes of which treatment is very costly. On account of growing awareness of obesity, there is a sudden rise in concern about being overweight due to which consumers are switching to anti-obesity drugs.
Self-esteem and confidence are few factors perceived to be lacking in obese people and to regain these attributes; the market is witnessing a rise in the use of anti-obesity drugs. In the current lifestyle where slim and the fit is considered the trend a lot of obese people feel the need to become fit to be accepted by the society. As obesity is being regarded as a particular medical problem rather than just a result of overeating, pharmaceutical companies are actively involved in the manufacturing of anti-obesity drugs to control the ailment.
Side effects such as the risk of psychiatric disorder, stroke is expected to impact the market growth over the forecast period negatively. Numerous anti-obesity drugs approved in the past decade such as Knoll and Acomplia (rimonabant) have been removed due to side effects such as suicidal thoughts, depression, and cardiovascular problems associated with their long-term usage. Owning to the factors as mentioned earlier, healthcare professionals have a negative perception of the anti-obesity drugs and do not advise them to consumers.
The growth of the anti-obesity drugs market is anticipated to be limited on account of high attrition rates. The transition of medicinal products from phase one to market is tough as more than 80% of the drugs get terminated before reaching pre-registration. It will lead to the low number of candidate drugs seen at the later stages of development.
Limited efficiency of currently available drugs and the unfavorable opinion of healthcare professionals and patients of anti-obesity drugs due to side effects and withdrawal following adverse post-marketing safety studies are hindrances to the market.
The global anti-obesity drugs market is segmented into two segments as centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs, by the way, it is used to treat a particular condition or the chemical type of the active ingredient used in its manufacturing. Due to the complexity of the disease, it's not very convenient to produce a single drug that is effective hence most of the anti-obesity drugs have to be administered together with proper diet and exercise.
Currently, the global anti-obesity drugs market is dominated by off-patent orlistat products. This dominance is mainly due to the performance of the recently approved Qsymia, which is superior in terms of efficacy to the current best option for the long-term treatment of obesity, namely orlistat and to any of the late-stage pipeline drugs.
Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population was obese in 2014. In developing countries, the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.
Takeda Pharmaceuticals America Inc’s drug Contrave, which is a mixture of two FDA approved drugs, naltrexone, and bupropion recently got approval from the FDA. This drug uses a different mechanism of a mesolimbic pathway to combat obesity. Development and approval of enhanced drugs are expected to augment the market demand for anti-obesity drugs.
Key market players in the global anti-obesity therapeutics market are Bristol-Myers Squibb, Eisai Company, GlaxoSmithKline plc, Novo Nordisk, Alizyme, Boehringer Ingelheim GmbH, Pfizer, Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Zafgen and Norgine Pharmaceuticals Ltd.
GlaxoSmithKline UK is the biggest drug manufacturing company, bought the rights to retail the world’s first over the counter anti-obesity medicine from its Swiss rival Roche. GlaxoSmithKline paid an initial amount of USD 100.0 million and royalty payments to Roche for the prescription drug under the brand Xenical. The drug prevents the fat consumed in food from being fully absorbed.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.